THOMAS E. DARCY - 20 Jun 2024 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Director
Signature
/s/ Michael E. Faerm, as Attorney-in-Fact
Issuer symbol
VIRX
Transactions as of
20 Jun 2024
Net transactions value
$0
Form type
4
Filing time
24 Jun 2024, 19:46:16 UTC
Previous filing
09 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 20 Jun 2024 Common Stock 50,000 $0.5690 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

Remarks:

Exhibit 24: Power of Attorney